{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:45:58Z","timestamp":1790721958074,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","primarycare.theclinics.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Primary Care: Clinics in Office Practice"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.pop.2016.07.012","type":"journal-article","created":{"date-parts":[[2016,11,18]],"date-time":"2016-11-18T05:37:31Z","timestamp":1479447451000},"page":"661-675","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":179,"title":["Lymphoma"],"prefix":"10.1016","volume":"43","author":[{"given":"Emiliano N.","family":"Mugnaini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilanjan","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pop.2016.07.012_bib1","unstructured":"National Institute of Health, National Cancer Institute. Cancer stat fact sheets. Available at: www.seer.cancer.gov\/statfacts\/html. Accessed May 8, 2016."},{"key":"10.1016\/j.pop.2016.07.012_bib2","series-title":"WHO classification of tumors of hematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"issue":"10","key":"10.1016\/j.pop.2016.07.012_bib3","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1182\/blood-2002-09-2778","article-title":"Utility of FDG-PET scanning in lymphoma by WHO classification","volume":"101","author":"Elstrom","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.pop.2016.07.012_bib4","first-page":"987","article-title":"A\u00a0predictive model for aggressive non-Hodgkin\u2019s lymphoma. The International Non-Hodgkin\u2019s lymphoma prognostic factors project","volume":"329","author":"Shipp","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pop.2016.07.012_bib5","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1200\/JCO.2009.26.2493","article-title":"Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era","volume":"28","author":"Ziepert","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.pop.2016.07.012_bib6","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.pop.2016.07.012_bib7","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.pop.2016.07.012_bib8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.pop.2016.07.012_bib9","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1200\/JCO.2007.13.6929","article-title":"Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014","volume":"26","author":"Persky","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.pop.2016.07.012_bib10","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","article-title":"Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study","volume":"33","author":"Nowakowski","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pop.2016.07.012_bib11","unstructured":"Grzegorz S, Nowakowski GS, Chiappella A, et\u00a0al. Randomized, phase III trial of the efficacy and safety of lenalidomide plus R-CHOP vs R-CHOP in patients with untreated ABC-type diffuse large B-cell lymphoma (DLC002; NCT02285062). American Society of Clinical Oncology Annual Meeting. Chicago, May 29 \u2013 June 2, 2015, [abstract: TPS8600]."},{"issue":"9","key":"10.1016\/j.pop.2016.07.012_bib12","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S1470-2045(14)70311-0","article-title":"Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study","volume":"15","author":"Younes","year":"2014","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.pop.2016.07.012_bib13","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"issue":"23","key":"10.1016\/j.pop.2016.07.012_bib14","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N\u00a0Engl J Med"},{"issue":"9873","key":"10.1016\/j.pop.2016.07.012_bib15","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.pop.2016.07.012_bib16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomized controlled trial","volume":"377","author":"Salles","year":"2010","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.pop.2016.07.012_bib17","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/gutjnl-2011-300495","article-title":"Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan","volume":"61","author":"Nakamura","year":"2012","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.pop.2016.07.012_bib18","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.pop.2016.07.012_bib19","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in\u00a0vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.pop.2016.07.012_bib20","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"29","key":"10.1016\/j.pop.2016.07.012_bib21","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"30","key":"10.1016\/j.pop.2016.07.012_bib22","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.pop.2016.07.012_bib23","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.pop.2016.07.012_bib24","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.pop.2016.07.012_bib25","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.pop.2016.07.012_bib26","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.pop.2016.07.012_bib27","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1200\/JCO.1996.14.3.925","article-title":"Adults and children with small noncleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen","volume":"14","author":"Magrath","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pop.2016.07.012_bib28","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1093\/annonc\/mdq677","article-title":"Evaluation of the addition of rituximab to\u00a0CODOX-M\/IVAC for Burkitt\u2019s lymphoma: a retrospective analysis","volume":"22","author":"Barnes","year":"2011","journal-title":"Ann Oncol"},{"issue":"20","key":"10.1016\/j.pop.2016.07.012_bib29","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa1308392","article-title":"Low-intensity therapy in adults with Burkitt's lymphoma","volume":"369","author":"Dunleavy","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pop.2016.07.012_bib30","unstructured":"Dunleavy K, Noy A, Abramson JS, et\u00a0al. Risk-adapted therapy in adults with Burkitt lymphoma: preliminary report of a multicenter prospective phase II study of DA-EPOCH-R. American Society of Hematology Annual Meeting. Orlando, December 5\u20138, 2015, [abstract: 342]."},{"issue":"18","key":"10.1016\/j.pop.2016.07.012_bib31","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"10.1016\/j.pop.2016.07.012_bib32","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.pop.2016.07.012_bib33","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"10.1016\/j.pop.2016.07.012_bib34","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-Cell Lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.pop.2016.07.012_bib35","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7","article-title":"Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP","volume":"36","author":"Bonadonna","year":"1975","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.pop.2016.07.012_bib36","doi-asserted-by":"crossref","first-page":"739","DOI":"10.7326\/0003-4819-104-6-739","article-title":"Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. a report of 8-year results","volume":"104","author":"Bonadonna","year":"1986","journal-title":"Ann Intern Med"},{"issue":"24","key":"10.1016\/j.pop.2016.07.012_bib37","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease","volume":"348","author":"Diehl","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.pop.2016.07.012_bib38","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1200\/JCO.20.3.630","article-title":"Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial","volume":"20","author":"Horning","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.pop.2016.07.012_bib39","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US Intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816","volume":"34","author":"Press","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.pop.2016.07.012_bib40","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pop.2016.07.012_bib41","doi-asserted-by":"crossref","unstructured":"Straus DJ, Pitcher B, Kostakoglu L, et\u00a0al. Initial results of US intergroup trial of response-adapted chemotherapy or chemotherapy\/radiation therapy based on PET for non-bulky stage I and II Hodgkin lymphoma (CALGB\/Alliance 50604). American Society of Hematology Annual Meeting. Orlando, December 5\u20138, 2015, [abstract: 578].","DOI":"10.1182\/blood.V126.23.578.578"},{"key":"10.1016\/j.pop.2016.07.012_bib42","unstructured":"Raemaekers J. Early FDG-PET adapted treatment improves the outcome of early FDG-PET-positive patients with stages I\/II Hodgkin lymphoma (HL): final results of the randomized intergroup EORTC\/LYSA\/FIL H10 trial. 13th International Conference on Malignant Lymphoma, Lugano (Switzerland), June 17\u201320, 2015, Late-Breaking Abstract."},{"key":"10.1016\/j.pop.2016.07.012_bib43","unstructured":"Gallamini A, Rossi A, Patti C, et\u00a0al. Interim PET-adapted chemotherapy in\u00a0advanced Hodgkin lymphoma. Results of the second interim analysis of the Italian GITIL\/FIL DH0607 trial. 13th International Conference on Malignant Lymphoma, Lugano (Switzerland), June 17\u201320, 2015, [abstract: 118]."},{"issue":"12","key":"10.1016\/j.pop.2016.07.012_bib44","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1182\/blood-2015-11-679407","article-title":"PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study","volume":"127","author":"Barrington","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.pop.2016.07.012_bib45","unstructured":"Johnson PW, Federico M, Foss\u00e5 A, et\u00a0al. Response-adapted therapy based on interim FDG-PET scans in advanced Hodgkin lymphoma: first analysis of the safety of de-escalation and efficacy of escalation in the international RATHL Study (CRUK\/07\/033). 13th International Conference on Malignant Lymphoma, Lugano (Switzerland), June 17\u201320, 2015, [abstract: 008]."},{"issue":"18","key":"10.1016\/j.pop.2016.07.012_bib46","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"10.1016\/j.pop.2016.07.012_bib47","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S1470-2045(13)70501-1","article-title":"Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study","volume":"14","author":"Younes","year":"2013","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.pop.2016.07.012_bib48","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pop.2016.07.012_bib49","doi-asserted-by":"crossref","unstructured":"Ansell S, Armand P, Timmerman JM, et\u00a0al. Nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma: clinical outcomes from extended follow-up of a Phase 1 study (CA209\u2013039). American Society of Hematology Annual Meeting. Orlando, December 5\u20138, 2015, [abstract: 583].","DOI":"10.1182\/blood.V126.23.583.583"},{"key":"10.1016\/j.pop.2016.07.012_bib50","doi-asserted-by":"crossref","unstructured":"Armand P, Shipp MA, Ribrag V, et\u00a0al. PD-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: safety, efficacy, and biomarker assessment. American Society of Hematology Annual Meeting. Orlando, December 5\u20138, 2015, [abstract: 584].","DOI":"10.1182\/blood.V126.23.584.584"}],"container-title":["Primary Care: Clinics in Office Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0095454316300525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0095454316300525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T10:59:55Z","timestamp":1601204395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0095454316300525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0095454316300525"],"URL":"https:\/\/doi.org\/10.1016\/j.pop.2016.07.012","relation":{},"ISSN":["0095-4543"],"issn-type":[{"value":"0095-4543","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Primary Care: Clinics in Office Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pop.2016.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}